!
JOACHIM(YAHALOM((NEW(YORK)(
IS(THERE(STILL(A(ROLE(FOR(COMBINED(MODALITY(THERAPY(FOR(EARLY(
STAGE(CLASSICAL(HODGKIN(LYMPHOMA?(?(PRO(
!!
The!discussion!will!Include:!
!
• The!evolvement!of!RT!in!HL!towards!smaller!volumes!and!lower!doses>!The!concept!
of!ISRT!
• Recent!data!from!randomized!studies!comparing!chemotherapy!alone!to!combined!
modality!therapy!in!PET!negative!and!PET>positive!patients!
• Risks!of!RT!in!the!modern!era!
• Risks!of!chemotherapy!alone!
• Salvage!options!and!its!consequences!
• Selection!of!patients!for!chemotherapy!alone!and!for!combined!modality!
• Quality!of!life!and!financial!toxicity!concerns!
! !
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES